Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Regional Nodal Recurrence after Treatment for Breast Cancer

Regional Nodal Recurrence after Treatment for Breast Cancer Purpose of ReviewRegional nodal recurrence (RNR) after breast cancer treatment is historically rare but associated with worse survival outcomes. The management of primary breast cancer has changed significantly, with less completion axillary dissection (ALND) and increased use of genomic testing, neoadjuvant therapy, and regional nodal irradiation. This review examines the incidence, risk factors, presentation, treatment, and prognosis of RNR in the context of modern breast cancer treatment.Recent FindingsThe rate of RNR recurrence is low (< 3%) in modern studies. Tumor biology and nodal burden play an important role in both risk of RNR and outcome. Combined locoregional and systemic therapy appears to provide the best outcome in the absence of systemic recurrence. Chemotherapy provides a survival benefit in estrogen receptor–negative patients only.SummaryRNR remains rare despite decreased ALND for node-positive disease. Treatment planning should be individualized based on tumor biology, prior treatment, and site and extent of recurrence. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Regional Nodal Recurrence after Treatment for Breast Cancer

Loading next page...
 
/lp/springer-journals/regional-nodal-recurrence-after-treatment-for-breast-cancer-jbCwffIN6W
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00392-x
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewRegional nodal recurrence (RNR) after breast cancer treatment is historically rare but associated with worse survival outcomes. The management of primary breast cancer has changed significantly, with less completion axillary dissection (ALND) and increased use of genomic testing, neoadjuvant therapy, and regional nodal irradiation. This review examines the incidence, risk factors, presentation, treatment, and prognosis of RNR in the context of modern breast cancer treatment.Recent FindingsThe rate of RNR recurrence is low (< 3%) in modern studies. Tumor biology and nodal burden play an important role in both risk of RNR and outcome. Combined locoregional and systemic therapy appears to provide the best outcome in the absence of systemic recurrence. Chemotherapy provides a survival benefit in estrogen receptor–negative patients only.SummaryRNR remains rare despite decreased ALND for node-positive disease. Treatment planning should be individualized based on tumor biology, prior treatment, and site and extent of recurrence.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Nov 6, 2020

There are no references for this article.